Clifford A. Hudis, MD: The Value of Progression-Free Survival (PFS)
Dr. Clifford Hudis, through his discussion of the trial showing bevacizumab (Avastin) slows metastatic breast cancer, he highlights the important topic of the value of progression-free survival (PFS). This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium.
Dr. Hudis is the Chief, Breast Cancer Medicine Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill-Cornell Medical College in New York City.
The Group Room at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium was made possible by support from:
